MAPT and Alzheimer disease: In particular, AD pathogenic proteins (Aβ, Tau, and various P-Tau species) have repeatedly been measured in NDEV preparations and have shown promise for AD clinical and preclinical diagnosis (Fiandaca et al., 2015; Kapogiannis et al., 2019; Eren et al., 2020; Eren et al., 2022).